Rabbit Monoclonal Recombinant Anti-Alpha-Synuclein Antibody from Abcam

Abcam’s recombinant anti-alpha-synuclein antibody detects only alpha-synuclein phosphorylated on Ser129.

  • Product Name - Anti-Alpha-synuclein (phospho S129) antibody [EP1536Y]
  • Description - Rabbit monoclonal [EP1536Y] to Alpha-synuclein (phospho S129)
  • Host Species - Rabbit
  • Specificity - The recombinant anti-alpha-synuclein antibody detects only alpha-synuclein phosphorylated on Ser129. The IHC-P antibody did not display any staining in human hippocampus normal brain but displayed staining in Parkinson’s brain, as predicted.
  • Tested Applications - Not suitable for IP, IHC-Fr, and Flow Cyt. Suitable for ICC/IF, IHC-P, ELISA, Dot blot, WB, and IHC-FrFl
  • Species Reactivity - It reacts with human, rat, and mouse.
  • Immunogen - Synthetic peptide within Human Alpha-synuclein aa 100 to the C-terminus. The precise sequence is proprietary.

Positive Control

  • Recombinant alpha-synuclein phosphorylated at S129
  • WB: Sarkosyl-insoluble brain extract from mice transgenic for PrPA53T alpha-synuclein
  • IHC-P: Human Parkinson Substantia Nigra tissue

General Notes

Abcam’s patented hybridoma-based technology - RabMAb® technology - is designed for producing rabbit monoclonal antibodies. This product is a recombinant rabbit monoclonal antibody.


Abcam’s Abpromise guarantee covers the usage of ab51253 in the tested applications listed in the table below. Recommended starting dilutions have been mentioned; the end-user should determine the ideal concentrations/dilutions.

Application Abreviews Notes
IHC-FrFl ☆☆☆☆☆ 1/5000.
WB ☆☆☆☆☆ 1/5000.
This detects a band of about 18 kDa (expected molecular weight: 14 kDa), and can be inhibited with Alpha-synuclein (phospho S129) peptide (ab188826). Excellent results have been achieved by treating the membrane with 0.4% PFA at room temperature for a period of 30 minutes prior to blocking it with 5% milk.
Dot blot Should be used at an assay dependent concentration.
ELISA Should be used at an assay dependent concentration.
IHC-P A concentration of 5–10 µg/mL should be used. Heat-mediated antigen retrieval should be performed with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC/IF ☆☆☆☆☆ Should be used at an assay dependent concentration.



The recombinant anti-alpha-synuclein antibody may play a role in the regulation of release and transport of dopamine. It induces fibrillization of the microtubule-associated protein tau. In addition, the antibody decreases neuronal responsiveness to numerous apoptotic stimuli, resulting in reduced caspase-3 activation.

Tissue Specificity

Although the antibody is mainly expressed in the brain, it is also expressed in all the examined tissues, but in low concentrations. However, it is not expressed in the liver. The antibody is concentrated in presynaptic nerve terminals.

Involvement in Disease

Genetic changes of SNCA, which lead to abnormal polymerization into fibrils, are linked with many neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates are a significant component of Lewy body (LB) inclusions, and represent the main non-A-beta component of Alzheimer disease amyloid plaque. They can also be found within glial inclusions, LB-like intraneuronal inclusions, and axonal spheroids in neurodegeneration with brain iron accumulation type 1.

  • Dementia Lewy body
  • Parkinson disease 4
  • Parkinson disease 1